Momenta Pharmaceuticals, Inc. - News/Events - Press Releases

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004

12/21/2015

Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study

12/21/2015

Baxalta and Momenta Announce M923, a Proposed HUMIRA (adalimumab) Biosimilar, Met Primary Endpoint in Pharmacokinetic Study

12/07/2015

Momenta Pharmaceuticals Appoints Matthew P. Ottmer as Chief Operating Officer

11/13/2015

Momenta Announces Temporary Pause of Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study

11/10/2015

Momenta Pharmaceuticals Announces U.S. Court of Appeals Decision to Remand Enoxaparin Case Back to District Court

11/06/2015

Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences

11/04/2015

Momenta Pharmaceuticals Reports Third Quarter 2015 Financial Results

10/28/2015

Momenta Pharmaceuticals to Webcast Presentation at the Credit Suisse 24th Annual Healthcare Conference

10/26/2015

Momenta Pharmaceuticals Announces Publication of Two Glatopa (glatiramer acetate injection) Manuscripts

10/21/2015

Momenta Pharmaceuticals Announces Date of Third Quarter 2015 Financial Results Conference Call and Webcast

10/05/2015

Baxalta and Momenta Announce Initiation of Pivotal Clinical Trial for M923, a Biosimilar Version of HUMIRA (adalimumab)

10/01/2015

Momenta Presents Three Glatopa (glatiramer acetate injection) Posters at ECTRIMS 2015 Meeting

09/18/2015

Momenta Pharmaceuticals Appoints Georges Gemayel, Ph.D., to Board of Directors

09/03/2015

Momenta Pharmaceuticals to Webcast Presentation at the Morgan Stanley Global Healthcare Conference

08/04/2015

Momenta Pharmaceuticals Reports Second Quarter 2015 Financial Results

07/21/2015

Momenta Pharmaceuticals Announces Date of Second Quarter 2015 Financial Results Conference Call and Webcast

06/25/2015

Momenta Pharmaceuticals Announces CFO Retirement and Succession Plan

06/18/2015

Momenta Pharmaceuticals Announces Launch of Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg

06/18/2015

Momenta Pharmaceuticals Announces CAFC Decision to Invalidate Remanded Teva Pharmaceuticals Patent in Daily COPAXONE(R) 20 mg Suit

06/04/2015

Momenta Pharmaceuticals Announces Oral and Poster Presentations Relating to Novel Autoimmune Programs at EULAR 2015

06/01/2015

Momenta Pharmaceuticals to Present New Data From Phase 1 Trial of Necuparanib in Patients With Pancreatic Cancer

05/26/2015

Momenta Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of Public Offering of Common Stock

05/19/2015

Momenta Pharmaceuticals Announces Pricing of Public Offering of Common Stock

05/18/2015

Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock

05/18/2015

Momenta Pharmaceuticals Announces Data Presentation on Necuparanib (M402) at the 2015 ASCO Annual Meeting

05/12/2015

Momenta Pharmaceuticals to Webcast Presentation at the UBS 2015 Global Healthcare Conference

05/06/2015

Momenta Pharmaceuticals to Webcast Presentation at the Bank of America Merrill Lynch 2015 Health Care Conference

05/01/2015

Momenta Pharmaceuticals to Webcast Presentation at the Deutsche Bank 40th Annual Health Care Conference

05/01/2015

Momenta Pharmaceuticals Reports First Quarter 2015 Financial Results

04/20/2015

Momenta Presents Key Glatopa(TM) (glatiramer acetate injection) Data at American Academy of Neurology Annual Meeting

04/17/2015

Momenta Pharmaceuticals Announces Data Presentations on Glatopa(TM) (glatiramer acetate injection) at the American Academy of Neurology's (AAN) 2015 Annual Meeting

04/16/2015

Momenta Pharmaceuticals Announces Conference Call Details Regarding FDA Approval for Glatopa(TM) (glatiramer acetate injection)

04/16/2015

Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg

04/15/2015

Momenta Pharmaceuticals Announces Date of First Quarter 2015 Financial Results Conference Call and Webcast

03/02/2015

Momenta Pharmaceuticals Announces Publication Revealing Development of a Novel Process to Generate High-Quality Hyper-sialylated IVIg Drug Candidate in PNAS

02/18/2015

Momenta Pharmaceuticals to Webcast Presentation at Cowen and Company's 35th Annual Health Care Conference

02/17/2015

Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results

02/03/2015

Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2014 Financial Results Conference Call and Webcast

01/29/2015

Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences

01/21/2015

Momenta Pharmaceuticals Announces Supreme Court Decision to Remand Generic Copaxone(R) Case Back to CAFC